RxDoctor Payments Data

Thomas Mladsi, MD

Cardiovascular Disease · Southfield, MINPI 1013907112

Payments from drug & device makers

$498in general payments, 2019–2025

Across 26 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$99
  • Alnylam Pharmaceuticals Inc.$80
  • Boehringer Ingelheim$77
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$64
  • Amgen$58
  • E.r. Squibb & Sons, L.L.C.$32
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$498100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$498 in reported general payments places this provider in the 20th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$113,510
Medicare patients
1,031
Services billed
2,330

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$293,375
XareltoRivaroxaban86$104,743
EntrestoSacubitril/Valsartan67$88,700
Repatha SureclickEvolocumab63$71,164
JardianceEmpagliflozin48$63,344
MultaqDronedarone Hcl29$43,183
FarxigaDapagliflozin Propanediol20$22,318
Praluent PenAlirocumab13$9,973
Rosuvastatin Calcium283$6,035
Metoprolol Succinate270$5,796
Flecainide Acetate81$4,447
Atorvastatin Calcium257$4,313
Ezetimibe148$4,167
Propafenone Hcl29$2,845
Losartan Potassium175$2,409

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$99$88,70067 claims
Boehringer IngelheimJardiance$77$63,34448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →